Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients
with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC).
Study population will consist of patients with CCR5-positive, locally advanced or metastatic
triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but
have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings
(first-line).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CytoDyn, Inc.
Collaborator:
Amarex Clinical Research
Treatments:
Carboplatin HIV Antibodies Leronlimab PRO-140 monoclonal antibody